Cover image for Nitric oxide donors for pharmaceutical and biological applications
Title:
Nitric oxide donors for pharmaceutical and biological applications
Publication Information:
Weiheim : Wiley-VCH, 2005
ISBN:
9783527310159

Available:*

Library
Item Barcode
Call Number
Material Type
Item Category 1
Status
Searching...
30000010080138 QK898.N58 N57 2005 Open Access Book Book
Searching...

On Order

Summary

Summary

Nitric oxide is a highly potent regulatory molecule with great pharmaceutical potential. This handbook fills a real gap in combining the chemistry of nitric oxide releasing substances with their practical applications in biology and drug design. It covers all classes of nitric oxide donors, from organic nitrates to nitroso compounds, guanidines and metal-NO complexes.
In addition to a detailed treatment of the chemistry of NO donors, numerous examples of successful diagnostic and pharmacological applications are discussed, as well as further therapeutic targets for these substances.


Author Notes

Peng George Wang obtained his B.S. degree in Chemistry from Nankai University, China in 1984 and his Ph.D. degree in organic chemistry from the University of California, Berkeley in 1990. He then conducted postdoctoral research at the Scripps Research Institute and in 1994 became an Assistant Professor at the University of Miami. From 1997 to 2003, he was a faculty member of Wayne State University. In 2003, he took his current position in the Departments of Biochemistry and Chemistry as Ohio Eminent Scholar in Macromolecular Structure and Function at the Ohio State University.
In 2002, Professor Wang has won the Isbell Award from the Divison of Carbohydrate Chemistry of the American Chemical Society.

Tingwei Bill Cai is a research assistant in Professor P. G. Wang's group at The Ohio State University. He studied chemistry at Peking University in China, where he completed his BS and MS degree in Medicinal Chemistry. Then he worked in National Institutes of Pharmaceutical Research & Development as a research scientist. In 2000, he joined Professor Wang's group. His main research focuses on drug design and synthesis. His research field covered carbohydrate, nucleic acid, heterocyclic and nitric oxide chemistry. He has published more than ten scientific papers. He is a member of American Chemical Society.

Naoyuki Taniguchi graduated from the Hokkaido University School of Medicine, followed by an M.D. degree in 1967, and completed the doctoral course of medicine at the Graduate School of Hokkaido University and obtained a Ph.D in 1972. He was then appointed assistant professor at the Hokkaido University School of Medicine in 1975 and was a visiting professor in the group of Dr. Alton Meister at Cornell University Medical College between 1976 and 1977. Returning to Hokkaido University, he joined the Biochemistry Laboratory at the Cancer Institute, before being appointed as a full professor at the Department of Biochemistry, Osaka University Medical School in 1986. Professor Taniguchi is an honorary member of the American Society for Biochemistry and Molecular Biology and has received numerous awards, among them the International Glycoconjugate Organization (IGO) Award in 2001.


Table of Contents

Preface.
List of Contributors.
Part I Neurological Disorders_Epidemiology, Clinical Overview, and Model Systems
1 StrokeAndreas Meisel and Konstantin Prass and Tilo Wolf and Ulrich Dirnagl Abstract.
1.1 Introduction.
1.2 The Penumbra Concept.
1.3 Excitotoxicity.
1.4 Oxygen Free Radicals.
1.5 Tissue Acidosis.
1.6 Peri-infarct Depolarizations.
1.7 Inflammation.
1.8 Damage to the Blood-Brain-Barrier.
1.9 Programmed Cell Death and Apoptosis.
1.10 Ischemia-induced DNA Damage, DNA Repair, and p53 as Genotoxic Sensor.
1.11 Epigenetics.
1.12 Gene Expression.
1.13 Cell Replacement.
1.14 Endogenous Neuroprotection - Ischemic Tolerance.
1.15 Stroke Induced Immune Depression (SIDS).
1.16 Conclusion.
References.
2 Parkinson's DiseaseMarina Romero-Ramos and Matthew Maingay and Deniz Kirik
2.1 Epidemiology of Parkinson's Disease.
2.2 Oxidative Stress In Parkinson's Disease.
2.3 Role of Alpha-Synuclein in Parkinson's Disease.
2.4 The Involvement of Proteosome in PD.
2.5 Other Genes Involved in Familial Parkinson's Disease.
2.6 Neurotoxic PD Models.
2.7 Genetic Models of Parkinson's Disease.
Acknowledgements.
References.
3 Amyotrophic Lateral SclerosisGeorg Haase
3.1 Human Motor Neuron Diseases.
3.2 Cell Culture Models of Motoneuron Degeneration.
3.3 Animal Models of Motor Neuron Disease.
3.4 Future Neuroprotective Approaches.
3.5 Conclusion.
References.
4 Alzheimer's Disease and Other Neurodegenerative DiseasesPhilipp J. Kahle and Christian Haass Abstract.
4.1 Introduction.
4.2 Transgenic Invertebrates.
4.3 Transgenic Mice.
4.4 Viral Models
4.5 Conclusion and Outlook.
References.
5 CNS InflammationChristine Stadelmann and Wolfgang Brnck
5.1 Introduction.
5.2 The Pathologic Characteristics of the MS Plaque.
5.3 Axonal Pathology in MS.
5.4 Neuronal Pathology in Multiple Sclerosis.
5.5 Lessons from Animal Models.
References.
6 NeurotraumaIbolja Cernak and Paul M. Lea IV and Alan I. Faden
6.1 Introduction.
6.2 In Vivo Models.
6.3 In Vitro Models.
6.4 Conclusion.
References.
7 Spinal Cord InjuryPoonam Verma and James W. Fawcett
7.1 Acute Neuroprotection (preventing neuronal death).
7.2 Regeneration of Nerve Fiber Tracts (initiating growth following injury).
7.3 Bridging Cysts and Scars and Cellular Replacement.
7.4 Replacing Lost Neurons.
7.5 Treating Demyelination.
7.6 Enhancing Plasticity.
7.7 Future Expectations.
References.
Part II Celluar and Molecular Mechanism
8 Apoptosis and NecrosisLaura Korhonen and Dan Lindholm
8.2 Introduction.
8.3 Apoptosis versus Necrosis.
8.4 Genetics of Apoptosis and the Proteins Involved.
8.5 Cellular Mechanisms of Apoptosis.
References.
9 Inflammation (Harald Neumann).
9.1 Introduction.
9.2 Innate Immune Responses in the CNS.
9.3 Dual Mechanism of Innate Immunity in the CNS.
9.4 Antigen Presentation for Adaptive Immune Responses in the CNS.
9.5 Regulation of Adaptive Immune Responses in the CNS.
9.6 Immune Surveillance of the CNS by T Lymphocytes.
9.7 Effector Mechanisms of Lymphocytes.
Acknowledgement.
References.
10 Metabolic DysfunctionsKonstantin-A. Hossmann
10.1 Introduction.
10.2 Disturbances of the Energy Metabolism.
10.3 Disturbances of Flow-coupling.
10.4 Mitochondrial Dysfunction.
10.5 Importance of Disturbed Energy Metabolism for Injury Evolution.
10.6 Disturbances of Protein Synthesis.
10.7 Importance of Disturbed Protein Synthesis on Injury Evolution.
10.8 Therapeutical Implications.
References.
11 Protein MisfoldingMilene Russelakis-Carneiro and Claudio Hetz and Joaquin Castilla and Claudio Soto Abstract.
11.1 Introduction.
11.2 Disease Propagation by Replication of Prion Prote